Therapeutic developments in pancreatic cancer: Current and future perspectives, Nat. Rev. Gastroenterol. Hepatol, vol.15, pp.333-348, 2018. ,
Optimal adjuvant chemotherapy for resected pancreatic adenocarcinoma: A systematic review and network meta-analysis, Oncotarget, vol.8, pp.81419-81429, 2017. ,
Targeting PI3K Signaling in Combination Cancer Therapy, Trends Cancer, vol.3, pp.454-469, 2017. ,
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets, Nat. Commun, vol.6, 2015. ,
Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110alpha, Genes Dev, vol.28, pp.2621-2635, 2014. ,
Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter?, Adv. Biol. Regul, vol.59, pp.19-35, 2015. ,
Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer, Cancer Cell, vol.23, pp.406-420, 2013. ,
PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice, Gastroenterology, vol.147, 2014. ,
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial, J. Clin. Oncol, vol.15, pp.174-195, 1997. ,
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies, Int. J. Mol. Sci, vol.18, 1338. ,
Targeted therapies for pancreatic cancer, Br. Med. Bull, vol.87, pp.97-130, 2008. ,
Targeted Therapies in Pancreatic Cancer: Promises and Failures, J. Cell. Biochem, 2017. ,
Therapeutic advances in pancreatic cancer, Gastroenterology, vol.144, pp.1316-1326, 2013. ,
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase I/II trial, J. Clin. Oncol, vol.29, pp.4548-4554, 2011. ,
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): From clinical trials to clinical practice, BMC Cancer, vol.16, 2016. ,
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N. Engl. J. Med, vol.364, pp.1817-1825, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00598658
FOLFIRINOX for locally advanced and metastatic pancreatic cancer: Single institution retrospective review of efficacy and toxicity, Med. Oncol, 2013. ,
A human proteome project with a beginning and an end, Proteomics, vol.4, pp.2519-2521, 2004. ,
Electrospray ionization for mass spectrometry of large biomolecules, Science, vol.246, pp.64-71, 1989. ,
Quantitative mass spectrometry in proteomics: Critical review update from 2007 to the present, Anal. Bioanal. Chem, vol.404, pp.939-965, 2012. ,
, A Balance between High-Throughput and In-Depth Analysis, vol.35, pp.598-609, 2017.
Mass spectrometry techniques for studying the ubiquitin system, Biochem. Soc. Trans, vol.45, pp.1137-1148, 2017. ,
Benchmarking common quantification strategies for large-scale phosphoproteomics, Nat. Commun, vol.9, 1045. ,
Annotating the human proteome: Beyond establishing a parts list, Biochim. Biophys. Acta, vol.1774, pp.175-191, 2007. ,
Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients, Ann. Oncol, vol.29, pp.223-229, 2018. ,
Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer, J. Natl. Cancer Inst, vol.109, 2017. ,
Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: Accurate detection of CA19-9 levels in pancreatic cancer, Proteomics, vol.8, pp.3051-3060, 2008. ,
Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms, Sci. Rep, 2015. ,
Plasma protein profiling of patients with intraductal papillary mucinous neoplasm of the pancreas as potential precursor lesions of pancreatic cancer, Clin. Chim. Acta, vol.477, pp.127-134, 2018. ,
Pancreatic preneoplastic lesions plasma signatures and biomarkers based on proteome profiling of mouse models, Br. J. Cancer, vol.113, pp.1590-1598, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01926958
Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma, Gastroenterology, vol.129, pp.1454-1463, 2005. ,
New pre-analytical approach for the deep proteome analysis of sera from pancreatitis and pancreas cancer patients, Arch. Physiol. Biochem, vol.116, pp.208-217, 2010. ,
MALDI imaging mass spectrometry for in situ proteomic analysis of preneoplastic lesions in pancreatic cancer, PLoS ONE, vol.7, 2012. ,
Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer, J. Proteom, vol.113, pp.400-402, 2015. ,
Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus, Clin. Cancer Res, vol.22, pp.1734-1743, 2016. ,
ITRAQ-based quantitative proteomics reveals apolipoprotein A-I and transferrin as potential serum markers in CA19-9 negative pancreatic ductal adenocarcinoma, Medicine ,
Comparison of the tumor cell secretome and patient sera for an accurate serum-based diagnosis of pancreatic ductal adenocarcinoma, Oncotarget, vol.8, pp.11963-11976, 2017. ,
Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach, Oncotarget, vol.8, pp.42761-42771, 2017. ,
Comparative proteomic profiling of the serum differentiates pancreatic cancer from chronic pancreatitis, vol.6, pp.1738-1751, 2017. ,
Increased circulating cell signalling phosphoproteins in sera are useful for the detection of pancreatic cancer, Br. J. Cancer, vol.103, pp.223-231, 2010. ,
Relative quantification of serum proteins from pancreatic ductal adenocarcinoma patients by stable isotope dilution liquid chromatography-mass spectrometry, J. Proteome Res, vol.11, pp.1749-1758, 2012. ,
Comparison of pancreas juice proteins from cancer versus pancreatitis using quantitative proteomic analysis, Pancreas, vol.34, pp.70-79, 2007. ,
Highly Accurate Identification of Cystic Precursor Lesions of Pancreatic Cancer Through Targeted Mass Spectrometry: A Phase IIc Diagnostic Study, J. Clin. Oncol, vol.36, pp.367-375, 2018. ,
Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma, Proteomics, vol.3, 1988. ,
Analysis of the pancreatic tumor progression by a quantitative proteomic approach and immunhistochemical validation, J. Proteome Res, vol.8, pp.1647-1656, 2009. ,
Quantification of pancreatic cancer proteome and phosphorylome: Indicates molecular events likely contributing to cancer and activity of drug targets, PLoS ONE, vol.9, 2014. ,
Reverse-phase protein array analysis to identify biomarker proteins in human pancreatic cancer, Dig. Dis. Sci, vol.59, pp.968-975, 2014. ,
Adaptive and reversible resistance to Kras inhibition in pancreatic cancer cells, Cancer Res, vol.78, pp.985-1002, 2018. ,
Modeling Therapy Response and Spatial Tissue Distribution of Erlotinib in Pancreatic Cancer, Mol. Cancer Ther, vol.15, pp.1145-1152, 2016. ,
, Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation. Cell, vol.165, 1818.
Secretome protein signature of human pancreatic cancer stem-like cells, J. Proteom, vol.136, pp.1-12, 2016. ,
Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach, Mol. Cell. Proteom, vol.5, pp.157-171, 2006. ,
Proteomic analysis of pancreatic cancer stem cells: Functional role of fatty acid synthesis and mevalonate pathways, J. Proteom, vol.150, pp.310-322, 2017. ,
Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling, Mol. Cell. Proteom, vol.15, pp.2671-2685, 2016. ,
Heterogeneity of pancreatic cancer metastases in a single patient revealed by quantitative proteomics, Mol. Cell. Proteom, vol.13, pp.2803-2811, 2014. ,
Temporal Effects of Combined Birinapant and Paclitaxel on Pancreatic Cancer Cells Investigated via Large-scale, Ion-Current-Based Quantitative Proteomics (IonStar), Mol. Cell. Proteom, vol.17, pp.655-671, 2018. ,
Options and considerations when selecting a quantitative proteomics strategy, Nat. Biotechnol, vol.28, pp.710-721, 2010. ,
Quantitative phosphoproteomics strategies for understanding protein kinase-mediated signal transduction pathways, Expert Rev. Proteom, vol.8, pp.81-94, 2011. ,
Biological signalling activity measurements using mass spectrometry, Biochem. J, vol.434, pp.189-199, 2011. ,
Optimizing targeted cancer therapy: Towards clinical application of systems biology approaches, Crit. Rev. Oncol. Hematol, vol.82, pp.171-186, 2012. ,
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group, J. Clin. Oncol, vol.25, pp.1960-1966, 2007. ,
Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer, Eur. J. Cancer, vol.49, pp.2633-2642, 2013. ,
Therapies for Pancreatic Cancer, Cancers, vol.10, 2018. ,
State of the art biological therapies in pancreatic cancer, World J. Gastrointest. Oncol, vol.8, pp.55-66, 2016. ,
Tumour heterogeneity and the evolution of polyclonal drug resistance, Mol. Oncol, vol.8, pp.1095-1111, 2014. ,
Cellular heterogeneity and molecular evolution in cancer, Annu. Rev. Pathol, vol.8, pp.277-302, 2013. ,
Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer, Nat. Genet, vol.49, pp.358-366, 2017. ,
Whole genomes redefine the mutational landscape of pancreatic cancer, Nature, vol.518, pp.495-501, 2015. ,
Genomic analyses identify molecular subtypes of pancreatic cancer, Nature, vol.531, pp.47-52, 2016. ,
Master Regulators of Oncogenic KRAS Response in Pancreatic Cancer: An Integrative Network Biology Analysis, PLoS Med, vol.14, 2017. ,
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy, Nat. Med, vol.17, pp.500-503, 2011. ,
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations, Cancer Cell, vol.31, 2017. ,
Heterogeneity of Phosphatidylinositol-3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin Activation in Cancer: Is PI3K Isoform Specificity Important? Front, vol.7, p.330, 2017. ,
S100 calcium-binding protein A6 promotes epithelial-mesenchymal transition through beta-catenin in pancreatic cancer cell line, PLoS ONE, vol.10, p.121319, 2015. ,
Identification of glycoprotein markers for pancreatic cancer CD24+CD44+ stem-like cells using nano-LC-MS/MS and tissue microarray, J. Proteome Res, vol.11, pp.2272-2281, 2012. ,
Mass spectrometry-assisted gel-based proteomics in cancer biomarker discovery: Approaches and application, vol.7, pp.3559-3572, 2017. ,
Recent advances in proteomic profiling of pancreatic ductal adenocarcinoma and the road ahead. Expert Rev, vol.14, pp.963-971, 2017. ,
Proteomics analysis of bodily fluids in pancreatic cancer, Proteomics, vol.15, pp.2705-2715, 2015. ,
Diagnostic significance of cancer-associated carbohydrate antigen (CA19-9) concentrations in pancreatic juice: Analysis in pure pancreatic juice collected by endoscopic aspiration and immunohistochemical study in chronic pancreatitis, Pancreas, vol.8, pp.151-159, 1993. ,
Proteome-based biomarkers in pancreatic cancer, World J. Gastroenterol, vol.17, pp.4845-4852, 2011. ,
Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers, Sci. Transl. Med, vol.9, 2017. ,
Glycoprotein biomarker panel for pancreatic cancer discovered by quantitative proteomics analysis, J. Proteome Res, vol.13, pp.1873-1884, 2014. ,
Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: A new concept for consistent and accurate proteome analysis, Mol. Cell. Proteom, vol.11, 2012. ,
SWATH mass spectrometry as a tool for quantitative profiling of the matrisome, J. Proteom, 2018. ,
The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling, Science, vol.332, pp.1317-1322, 2011. ,
Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling, Science, vol.332, pp.1322-1326, 2011. ,
Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer, Clin. Cancer Res, vol.21, pp.396-404, 2015. ,
Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer, Mol. Cancer Ther, vol.14, pp.40-47, 2015. ,
Genetics and biology of pancreatic ductal adenocarcinoma, Genes Dev, vol.30, pp.355-385, 2016. ,
Trichostatin A alters cytoskeleton and energy metabolism of pancreatic adenocarcinoma cells: An in depth proteomic study, J. Cell. Biochem, vol.119, pp.2696-2707, 2018. ,
Peptide microarrays for detailed, high-throughput substrate identification, kinetic characterization, and inhibition studies on protein kinase A, Anal. Biochem, vol.387, pp.150-161, 2009. ,
Comprehensive Analysis of Cancer-Proteogenome to Identify Biomarkers for the Early Diagnosis and Prognosis of Cancer, vol.5, 2017. ,
Molecular signaling network complexity is correlated with cancer patient survivability, Proc. Natl. Acad. Sci, vol.109, pp.9209-9212, 2012. ,
Endoscopic ultrasound-guided fine-needle aspiration plus KRAS and GNAS mutation in malignant intraductal papillary mucinous neoplasm of the pancreas, Endosc. Int. Open, vol.4, pp.1228-1235, 2016. ,